Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
-
BUSINESS Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
-
REGULATORY Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
-
REGULATORY Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
-
BUSINESS Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
-
BUSINESS Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
-
REGULATORY Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
-
BUSINESS Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
-
BUSINESS Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
-
BUSINESS Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
-
BUSINESS Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
-
BUSINESS “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
-
BUSINESS Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
-
BUSINESS Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
-
BUSINESS Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
-
BUSINESS Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
-
BUSINESS Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
-
BUSINESS Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
-
REGULATORY MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
-
BUSINESS “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…